DanCann Pharma A/S intends to resolve on a partially (77 percent) guaranteed rights issue of approximately DKK 28.5 million
COPENHAGEN, Denmark, August 31, 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the Board of Directors in DanCann Pharma today announces its intention to resolve on a partially (77 percent) guaranteed rights issue of units corresponding to a total of approximately DKK 28.5 million (the “Rights Issue”). An Extraordinary General Meeting (“EGM”) is proposed to authorize the Board of Directors to resolve on the Rights Issue. The EGM is planned to be held on 20 September 2022 and the notice will be published